Safety and toxicity summary for infused patients
| Event/grade . | Inotuzumab-naïve; N (%) . | Inotuzumab-exposed; N (%) . | P-value . |
|---|---|---|---|
| CRS, evaluable patients | |||
| Any | 71 (83) | 86 (85) | 0.63 |
| Grade 1-2 | 66 (93) | 71 (83) | 0.05 |
| Grade 3-4 | 5 (7) | 15 (17) | |
| Median days to onset | 5 | 5 | 0.47 |
| ICANS, evaluable patients | |||
| Any | 50 (57) | 55 (54) | 0.68 |
| Grade 1-2 | 28 (56) | 18 (33) | 0.02 |
| Grade 3-4 | 22 (44) | 37 (67) | |
| Median days to onset | 7 | 7 | 0.52 |
| Toxicity management, evaluable patients | |||
| Tocilizumab | 61 (70) | 68 (67) | 0.61 |
| Steroids | 58 (67) | 63 (62) | 0.48 |
| Anakinra | 17 (20) | 27 (26) | 0.26 |
| Hospital length of stay, median days (range) | 14 (4-91) | 15 (0-95) | 0.24 |
| Early death | |||
| Within 30 days of infusion | 3 (3) | 10 (10) |
| Event/grade . | Inotuzumab-naïve; N (%) . | Inotuzumab-exposed; N (%) . | P-value . |
|---|---|---|---|
| CRS, evaluable patients | |||
| Any | 71 (83) | 86 (85) | 0.63 |
| Grade 1-2 | 66 (93) | 71 (83) | 0.05 |
| Grade 3-4 | 5 (7) | 15 (17) | |
| Median days to onset | 5 | 5 | 0.47 |
| ICANS, evaluable patients | |||
| Any | 50 (57) | 55 (54) | 0.68 |
| Grade 1-2 | 28 (56) | 18 (33) | 0.02 |
| Grade 3-4 | 22 (44) | 37 (67) | |
| Median days to onset | 7 | 7 | 0.52 |
| Toxicity management, evaluable patients | |||
| Tocilizumab | 61 (70) | 68 (67) | 0.61 |
| Steroids | 58 (67) | 63 (62) | 0.48 |
| Anakinra | 17 (20) | 27 (26) | 0.26 |
| Hospital length of stay, median days (range) | 14 (4-91) | 15 (0-95) | 0.24 |
| Early death | |||
| Within 30 days of infusion | 3 (3) | 10 (10) |
CRS, cytokine release syndrome; ICANS, immune effector cell associated neurotoxicity syndrome; WBC, white blood cell.